MedTrace Logo

Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants

NCT00197769 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-08-29

No results posted yet for this study

Summary

The purpose of the trial is to determine the minimum of doses of a new nine valent pneumococcal conjugate vaccine required to protect UK infants and toddlers

Conditions

  • Streptococcus Pneumoniae

Interventions

BIOLOGICAL

9 valent pneumococcal con jugate vaccine

Sponsors & Collaborators

  • Public Health England

    lead OTHER_GOV

Principal Investigators

  • Elizabeth Miller, MBBS FRCPath · Public Health England

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Weeks
Max Age
18 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-09-30
Completion
2004-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00197769 on ClinicalTrials.gov